Serina Therapeutics, Inc. (SER) Financial Ratios
9 years of historical data (2016–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
25.35
↓-65% vs avg
5yr avg: 72.58
30Y Low12.9·High72.6
ROE
-2193.1%
+0% vs avg
5yr avg: -2193.1%
30Y Low-224%·High-79%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SER Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Serina Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $37M | $116M | $21M | $42M | $58M | $69M | $106M | — | — |
| Enterprise Value | $15M | $33M | $112M | $39M | $55M | $64M | $68M | $99M | — | — |
| P/E Ratio → | -1.16 | — | 21.83 | — | — | — | — | — | — | — |
| P/S Ratio | 337.05 | 658.37 | 36.69 | 42.53 | 13.80 | 1076.81 | 39.86 | 75.94 | — | — |
| P/B Ratio | 25.35 | 72.58 | — | — | — | — | 26.32 | 12.88 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SER EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 597.58 | 35.37 | 77.49 | 17.95 | 1183.64 | 39.63 | 71.14 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 19.14 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
SER Profitability
Margins and return-on-capital ratios measuring operating efficiency
Serina Therapeutics, Inc. earns an operating margin of -30442.9%. Operating margins have compressed from -454.1% to -30442.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -2193.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -246.4% | -246.4% | 97.1% | 100.0% | 100.0% | -2272.2% | 42.2% | 39.8% | 51.2% | 45.3% |
| Operating Margin | -30442.9% | -30442.9% | -99.2% | -454.1% | -53.7% | -19272.2% | -726.8% | -748.2% | -599.5% | -764.6% |
| Net Profit Margin | -19894.6% | -19894.6% | 167.1% | -536.4% | -41.6% | -20120.4% | -703.4% | -537.4% | -468.7% | -929.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2193.1% | -2193.1% | — | — | — | — | -224.1% | -90.7% | -79.1% | — |
| ROA | -142.0% | -142.0% | 86.3% | -83.9% | -35.7% | -191.2% | -134.2% | -73.9% | -102.4% | -480.7% |
| ROIC | — | — | — | -375.5% | -219.3% | -601.8% | -503.0% | -634.8% | -668.7% | — |
| ROCE | -286.2% | -286.2% | -871.6% | — | — | -767.2% | -203.0% | -126.2% | -101.2% | — |
SER Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $268000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.53 | 0.53 | — | — | — | — | 0.75 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -6.70 | — | — | — | — | -0.15 | -0.81 | -0.89 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -32.41 | -32.41 | -5.61 | -142.99 | -527.31 | -25.76 | — | — | -701.42 | -509.56 |
Net cash position: cash ($4M) exceeds total debt ($268000)
SER Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Serina Therapeutics, Inc.'s current ratio of 2.40x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.24x to 2.40x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.40 | 2.40 | 5.39 | 0.24 | 0.25 | 0.43 | 1.23 | 3.22 | 5.79 | 0.03 |
| Quick Ratio | 2.40 | 2.40 | 5.39 | 0.24 | 0.25 | 0.43 | 1.23 | 3.22 | 5.79 | 0.03 |
| Cash Ratio | 1.55 | 1.55 | 5.39 | 0.06 | 0.07 | 0.10 | 0.71 | 2.75 | 5.62 | 0.01 |
| Asset Turnover | — | 0.01 | 0.35 | 0.15 | 0.96 | 0.01 | 0.23 | 0.13 | 0.15 | 0.52 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 2.92 | 3.00 | 2203.52 | 76.68 | 34.25 | 27.82 | 67.48 |
SER Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Serina Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 4.6% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $8M | $1M | $1M | $1M | $1M | $992721 | $1M | $1M |
Peer Comparison
Compare SER with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SERYou | $19M | -1.2 | — | — | -246.4% | -30442.9% | -2193.1% | — | — |
 PRTA | $578M | -2.4 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACAD | $4B | 9.8 | 26.7 | 36.5 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 BIIB | $29B | 21.9 | 11.6 | 13.9 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 ALNY | $39B | 126.6 | 70.0 | 84.6 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $13B | -31.8 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARVN | $647M | -7.9 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 PTGX | $6B | -48.5 | — | 113.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 DNLI | $3B | -6.6 | — | — | — | — | -45.7% | -42.8% | — |
 CRL | $9B | -61.0 | 12.7 | 16.9 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See SER's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SER Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SER vs PRTA
Side-by-side business, growth, and profitability comparison vs Prothena Corporation plc.
Start ComparisonSER — Frequently Asked Questions
Quick answers to the most common questions about buying SER stock.
What is Serina Therapeutics, Inc.'s P/E ratio?
Serina Therapeutics, Inc.'s current P/E ratio is -1.2x. The historical average is 21.8x.
What is Serina Therapeutics, Inc.'s ROE?
Serina Therapeutics, Inc.'s return on equity (ROE) is -2193.1%. The historical average is -131.3%.
Is SER stock overvalued?
Based on historical data, Serina Therapeutics, Inc. is trading at a P/E of -1.2x. Compare with industry peers and growth rates for a complete picture.
What are Serina Therapeutics, Inc.'s profit margins?
Serina Therapeutics, Inc. has -246.4% gross margin and -30442.9% operating margin.